About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

NCT00161668·59 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Wyeth is now a wholly owned subsidiary of Pfizer

Age

18–65

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Treated by Mylotarg
Provide ICF

The record

StatusCompleted

PhaseNo phase

Taking part500

StartedOct 2001

UpdatedMar 15, 2007

Conditions

Acute Myeloid Leukemia

Where59

Tucson, Arizona, United States
Berkely, California, United States
Burbank, California, United States

Clareo Health | Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care